Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Pluri Inc.(PLUR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PLUR
09/25/2026: PLUR (1-star) is currently NOT-A-BUY. Pass it for now.
Pluri Inc. is a biotechnology company that leverages its proprietary 3D cell expansion technology to develop therapeutic products and support the cultivated food and CDMO industries. Its primary strength lies in this versatile, scalable platform, which offers a diversified business model beyond traditional clinical-stage drug development. The main investment story centers on the commercial success of its cell-based therapies and the adoption of its bioreactor technology across medical and food-tech sectors. However, the company faces significant execution risks related to clinical success, market adoption, and a consistent need for external financing. Pluri is best suited for growth-oriented investors with a high risk tolerance and a long-term outlook.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Investors must have a high tolerance for risk and a very long time horizon to see potential returns from clinical-stage biotech. |
| Momentum investor | Mixed fit | The stock can exhibit high volatility based on clinical trial results, which may attract momentum strategies during specific news cycles. |
| Value investor | Weak fit | Pluri does not currently generate consistent earnings or cash flows, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes cash preservation for R&D. |
| Low-risk investor | Weak fit | The high volatility and clinical binary-outcome risks are inappropriate for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The share price is sensitive to clinical trial announcements and financing news. |
| Valuation risk | High | Valuing pre-revenue companies is inherently speculative and subject to significant correction. |
| Competition risk (biotech/cell-therapy) | Medium / high | Significant competition exists from better-capitalized pharmaceutical entities. |
| Business quality | Medium | The company possesses specialized intellectual property but lacks established, profitable commercial scale. |
| Dividend income | Low / none | There is no income potential for investors. |
| Execution risk | High | Success depends on managing complex clinical trials and scaling manufacturing technology. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -73.71% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.96M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 25.5K shares | Beta 0.67 | 52 Weeks Range 0.98 - 4.87 | Updated Date 09/25/2026 |
52 Weeks Range 0.98 - 4.87 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.44 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy | Clinical-stage development of PLX cell products for medical treatments. | Revenue is speculative and tied to clinical trial progress and potential licensing. |
| CDMO Services | Contract manufacturing services for third-party biotech clients. | Provides a potential source of recurring revenue as the company scales its equipment. |
| Food-Tech JVs | Collaborations using cell-expansion tech for cultivated food solutions. | A long-term, high-risk bet on the future of food production. |
Valuation
Trailing PE - | Forward PE 3.63 | Enterprise Value 40.20M | Price to Sales(TTM) 12.76 |
Enterprise Value 40.20M | Price to Sales(TTM) 12.76 | ||
Enterprise Value to Revenue 39.56 | Enterprise Value to EBITDA -1.28 | Shares Outstanding 12.34M | Shares Floating 6.12M |
Shares Outstanding 12.34M | Shares Floating 6.12M | ||
Percent Insiders 42.52 | Percent Institutions 20.68 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Pluri Inc.
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2003-06-30 | President, CEO & Director Mr. Yaacov Yanay | ||
Sector Healthcare | Industry Biotechnology | Full time employees 92 | Website https://www.pluri-biotech.com |
Full time employees 92 | Website https://www.pluri-biotech.com | ||
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.